Table 2

Relative ORs between active treatments estimated from the Bayesian hierarchical model for the outcomes of response (lower triangle) and withdrawals (upper triangle). Values larger than 1 favour the treatment in the column for response and the treatment in the row for withdrawals. Treatments have been ordered from top to bottom according to their relative ranking for efficacy

LOR0.32 (0.03–2.21)0.78 (0.31–1.99)0.31 (0.11–0.93)0.77 (0.33–1.75)0.60 (0.24–1.51)0.48 (0.24–0.94)0.70 (0.28–1.84)0.93 (0.39–2.19)
1.04 (0.31–3.44)FLUO2.41 (0.37–23.03)0.95 (0.13–9.80)2.34 (0.41–20.48)1.84 (0.28–17.64)1.47 (0.24–13.61)2.16 (0.34–20.92)2.84 (0.46–25.92)
1.31 (0.57–3.08)1.27 (0.39–4.35)DULO0.40 (0.15–1.07)0.98 (0.46–2.04)0.77 (0.40–1.42)0.61 (0.28–1.30)0.89 (0.39–2.09)1.19 (0.55–2.51)
1.20 (0.56–2.68)1.15 (0.37–3.83)0.91 (0.46–1.87)SER2.47 (0.95–6.02)1.93 (0.71–5.00)1.55 (0.58–3.79)2.24 (0.82–6.05)2.99 (1.15–7.39)
1.21 (0.62–2.31)1.16 (0.41–3.36)0.92 (0.47–1.75)1.01 (0.55–1.73)VEN0.78 (0.37–1.63)0.63 (0.33–1.16)0.91 (0.43–2.04)1.21 (0.70–2.10)
1.29 (0.52–3.13)1.24 (0.36–4.39)0.98 (0.48–1.97)1.08 (0.47–2.34)1.06 (0.52–2.22)ESC0.80 (0.37–1.70)1.17 (0.51–2.76)1.55 (0.73–3.28)
1.30 (0.71–2.36)1.24 (0.42–3.87)0.98 (0.48–1.98)1.08 (0.56–1.98)1.07 (0.69–1.70)1.00 (0.47–2.17)PREG1.46 (0.67–3.34)1.95 (0.99–3.86)
1.82 (0.87–3.83)1.76 (0.58–5.58)1.39 (0.66–2.87)1.52 (0.77–2.88)1.50 (0.91–2.57)1.41 (0.65–3.14)1.41 (0.80–2.51)PAR1.33 (0.59–2.86)
1.67 (0.23–11.62)1.61 (0.19–13.56)1.28 (0.18–8.71)1.39 (0.20–9.22)1.39 (0.21–8.89)1.30 (0.18–9.20)1.30 (0.19–8.46)0.92 (0.13–6.04)QUE
1.20 (0.61–2.38)1.16 (0.40–3.52)0.91 (0.47–1.79)1.00 (0.54–1.78)0.99 (0.69–1.49)0.93 (0.45–1.97)0.93 (0.57–1.52)0.66 (0.39–1.13)0.72 (0.11–4.87)TIAG
  • DULO, duloxetine; ESC, escitalopram; FLUO, fluoxetine; LOR, lorazepam; PAR, paroxetine; PREG, pregabalin; QUE, quetiapine; SER, sertraline; TIAG, tiagabine; VEN, venlafaxine.